- Home
- SW vs BIIB Comparison
SW vs BIIB Comparison
Compare SW & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SW
- BIIB
- Stock Information
- Founded
- SW 1934
- BIIB 1978
- Country
- SW Ireland
- BIIB United States
- Employees
- SW N/A
- BIIB N/A
- Industry
- SW
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- SW
- BIIB Health Care
- Exchange
- SW Nasdaq
- BIIB Nasdaq
- Market Cap
- SW 28.4B
- BIIB 25.1B
- IPO Year
- SW N/A
- BIIB 1991
- Fundamental
- Price
- SW $54.53
- BIIB $149.02
- Analyst Decision
- SW Buy
- BIIB Buy
- Analyst Count
- SW 8
- BIIB 26
- Target Price
- SW $59.75
- BIIB $248.00
- AVG Volume (30 Days)
- SW 3.3M
- BIIB 1.6M
- Earning Date
- SW 02-19-2025
- BIIB 02-11-2025
- Dividend Yield
- SW 2.22%
- BIIB N/A
- EPS Growth
- SW N/A
- BIIB 10.05
- EPS
- SW 0.68
- BIIB 11.06
- Revenue
- SW $16,432,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- SW $140.42
- BIIB N/A
- Revenue Next Year
- SW $14.38
- BIIB N/A
- P/E Ratio
- SW $80.23
- BIIB $13.47
- Revenue Growth
- SW 27.83
- BIIB N/A
- 52 Week Low
- SW $38.55
- BIIB $145.07
- 52 Week High
- SW $56.99
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- SW N/A
- BIIB 32.44
- Support Level
- SW N/A
- BIIB $145.07
- Resistance Level
- SW N/A
- BIIB $149.92
- Average True Range (ATR)
- SW 0.00
- BIIB 3.81
- MACD
- SW 0.00
- BIIB 0.05
- Stochastic Oscillator
- SW 0.00
- BIIB 22.51
About SW Smurfit WestRock plc Ordinary Shares
Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.